Les hépatites virales et la consommation de drogues en Europe
Cette publication rend compte des hépatites virales et de la consommation de drogues en Europe, en se concentrant sur la promotion de traitements pour les injecteurs de drogues et sur leur décriminalisation. Pour en savoir plus, en anglais, veuillez lire les informations ci-dessous.
Abonnez-vous à l'Alerte mensuelle de l'IDPC pour recevoir des informations relatives à la politique des drogues.
This publication has been produced with the financial support of the Drug Prevention and Information Programme (DPIP) of the European Union. The contents of this publication are the sole responsibility of the authors and can in no way be taken to reflect the view of the European Commission. The publication charges for this supplement were funded by AbbVie as an unresitricted grant to Rigshospitalet, the University of Copenhagen, Denmark.
Introduction
Hepatitis – a devastating epidemic in Europe
Jeffrey V Lazarus, Kevin A FentonBMC Infectious Diseases 2014, 14(Suppl 6):S1 (19 September 2014)
Full text | PDF | PubMed
Commentary
No strategy to meet the HCV epidemic
Olav Dalgard, Stefan MaussBMC Infectious Diseases 2014, 14(Suppl 6):S2 (19 September 2014)
Full text | PDF | PubMed
Commentary
Improved hepatitis C screening and treatment in people who inject drugs should be a priority in Europe
Achim Kautz, Lilyana Chavdarova, Margaret WalkerBMC Infectious Diseases 2014, 14(Suppl 6):S3 (19 September 2014)
Full text | PDF | PubMed
Commentary
Ending the mass criminalisation of people who use drugs: a necessary component of the public health response to hepatitis C
Chris Ford, Juliet BressanBMC Infectious Diseases 2014, 14(Suppl 6):S4 (19 September 2014)
Full text | PDF | PubMed
Commentary
A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients
Maria Phelan, Catherine CookBMC Infectious Diseases 2014, 14(Suppl 6):S5 (19 September 2014)
Full text | PDF | PubMed
Commentary
A national multidisciplinary healthcare network for treatment of hepatitis C in people who inject drugs in Slovenia
Mojca MaticicBMC Infectious Diseases 2014, 14(Suppl 6):S6 (19 September 2014)
Full text | PDF | PubMed
Commentary
The successful implementation of Scotland’s Hepatitis C Action Plan: what can other European stakeholders learn from the experience? A Scottish voluntary sector perspective
Leon Wylie, Sharon Hutchinson, David Liddell, Nicola RowanBMC Infectious Diseases 2014, 14(Suppl 6):S7 (19 September 2014)
Full text | PDF | PubMed
Commentary
Improving the quality of needle and syringe programmes: an overlooked strategy for preventing hepatitis C among people who inject drugs
Astrid LeichtBMC Infectious Diseases 2014, 14(Suppl 6):S8 (19 September 2014)
Full text | PDF | PubMed
Commentary
Consensus for the integrated management of hepatitis C in Portugal
Ricardo LeiteBMC Infectious Diseases 2014, 14(Suppl 6):S9 (19 September 2014)
Full text | PDF | PubMed
Commentary
A perspective from drug user organisations on ‘ECDC and EMCDDA guidance: prevention and control of infectious diseases among people who inject drugs’
Antonio Corbacho, Manuel Rivera, Francisco Trujillo, Maite Martí, José Carbonell, Francisco Fernández, Alexandre Rosselló, Jordi Perramon, Jaume Salse, Ignacio RamosBMC Infectious Diseases 2014, 14(Suppl 6):S10 (19 September 2014)
Full text | PDF | PubMed
Commentary
A policy-maker’s perspective on ‘ECDC and EMCDDA guidance: prevention and control of infectious diseases among people who inject drugs’
Joan Colom I FarranBMC Infectious Diseases 2014, 14(Suppl 6):S11 (19 September 2014)
Full text | PDF | PubMed
Research
Hepatitis C virus seroprevalence among people who inject drugs and factors associated with infection in eight Russian cities
Robert Heimer, Ksenia Eritsyan, Russell Barbour, Olga S LevinaBMC Infectious Diseases 2014, 14(Suppl 6):S12 (19 September 2014)
Abstract | Full text | PDF | PubMed
Review
HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective
Lars Peters, Amanda Mocroft, Jens Lundgren, Daniel Grint, Ole Kirk, Jürgen RockstrohBMC Infectious Diseases 2014, 14(Suppl 6):S13 (19 September 2014)
Full text | PDF | PubMed
Research
Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries
Mojca Maticic, Jerneja Videcnik Zorman, Sergeja Gregorcic, Eberhard Schatz, Jeffrey V LazarusBMC Infectious Diseases 2014, 14(Suppl 6):S14 (19 September 2014)
Abstract | Full text | PDF | PubMed
Research
Policy responses to viral hepatitis B and C among people who inject drugs in Member States of the WHO European region: a sub-analysis of the WHO 2013 global hepatitis policy survey
Alexander Spina, Irina Eramova, Jeffrey V LazarusBMC Infectious Diseases 2014, 14(Suppl 6):S15 (19 September 2014)
Abstract | Full text | PDF | PubMed
Research
A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region
Jeffrey V Lazarus, Ida Sperle, Mojca Maticic, Lucas WiessingBMC Infectious Diseases 2014, 14(Suppl 6):S16 (19 September 2014)
Abstract | Full text | PDF | PubMed
Review
Hepatitis C in European prisons: a call for an evidence-informed response
Amber Arain, Geert Robaeys, Heino StöverBMC Infectious Diseases 2014, 14(Suppl 6):S17 (19 September 2014)
Abstract | Full text | PDF | PubMed
Roundtable
Roundtable discussion: how lessons learned from HIV can inform the global response to viral hepatitis
Jeffrey V Lazarus, Jens Lundgren, Jordi Casabona, Lucas Wiessing, Catharina Matheï, Peter Vickerman, Maria Prins, Mirjam Kretzschmar, Maria Kantzanou, Isabelle Giraudon, Marica Ferri, Paul Griffiths, Magdalena Harris, Margaret Walker, Lilyana Chavdarova, Eberhard Schatz, Katrin Schiffer, John Kools, Jason Farell, Luís MendãoBMC Infectious Diseases 2014, 14(Suppl 6):S18 (19 September 2014)
Full text | PDF | PubMed
Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.